Seres Therapeutics, Inc.
MCRB
$17.03
$0.331.98%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 351.00K | -- | -- | -- | 64.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 351.00K | -- | -- | -- | 64.00K |
| Cost of Revenue | 25.10M | 26.24M | 27.42M | 23.89M | 21.78M |
| Gross Profit | -24.74M | -26.24M | -27.42M | -23.89M | -21.78M |
| SG&A Expenses | 44.08M | 47.31M | 50.13M | 53.18M | 54.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.78M | 110.12M | 114.11M | 121.31M | 129.50M |
| Operating Income | -103.43M | -110.12M | -114.11M | -121.31M | -129.50M |
| Income Before Tax | 5.39M | -53.85M | -60.19M | -125.77M | -144.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.39 | -53.85 | -60.19 | -125.77 | -144.85 |
| Earnings from Discontinued Operations | 0.00 | 139.81M | 133.14M | 125.91M | 119.38M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.39M | 85.97M | 72.95M | 136.00K | -25.48M |
| EBIT | -103.43M | -110.12M | -114.11M | -121.31M | -129.50M |
| EBITDA | -99.17M | -105.50M | -109.13M | -115.85M | -123.49M |
| EPS Basic | 0.60 | 11.29 | 9.22 | -0.03 | -4.54 |
| Normalized Basic EPS | -4.04 | -6.86 | -7.59 | -9.00 | -12.49 |
| EPS Diluted | 0.52 | 11.22 | 9.15 | -0.10 | -4.56 |
| Normalized Diluted EPS | -4.03 | -6.86 | -7.59 | -9.00 | -12.49 |
| Average Basic Shares Outstanding | 34.77M | 33.64M | 32.48M | 31.08M | 29.02M |
| Average Diluted Shares Outstanding | 34.80M | 33.66M | 32.49M | 31.08M | 29.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |